Visão geral da empresa
A clinical biotechnology company named Indaptus Therapeutics, Inc., operating under the ticker symbol INDP, focuses on the development of immunotherapy products designed to combat cancer and viral infections. The firm's primary strategic asset is its lead clinical candidate, Decoy20, which is engineered to generate durable responses through single agent activity or as part of combination therapy-based approaches. This entity functions within the broader Healthcare sector and specifically the Biotechnology industry, sectors characterized by high research and development expenditures and long product development cycles. The company maintains a very small operational scale, employing only five individuals and holding a market capitalization of $4.15M. The negligible annual revenue, recorded as N/A, combined with the minimal market cap, indicates that the company is in an early-stage development phase where value is derived from intellectual property potential rather than current commercial sales, distinguishing it from mature pharmaceutical peers that generate significant cash flow from established product portfolios.
Saúde financeira
The financial performance metrics for Indaptus Therapeutics reveal a deep negative net income of $-20,848,916 and an EBITDA of $-19,832,778 over the trailing twelve-month period, while revenue remains N/A. The substantial gap between the non-existent revenue and the massive net loss highlights a cost structure entirely driven by operational burn and research expenses rather than sales overhead. The company generated a free cash flow of $-8,159,969, which signifies a continuous consumption of cash reserves necessary to fund its clinical trials and operational infrastructure without external financing. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the standard accounting treatment for pre-revenue biotech firms where cost of goods sold and operating expenses exceed any nominal revenue or are simply not yet realized. On the balance sheet, the company holds $8.51M in cash against $0 in debt, presenting a situation where the debt-to-equity ratio is N/A due to the absence of leverage. This cash position provides a buffer against the high cash burn rate, though the total liquidity is limited relative to the cumulative annual losses. The current ratio stands at 1.51, indicating that the company possesses $1.51 in current assets for every $1.00 of current liabilities, suggesting a conservative stance on short-term liquidity management despite the lack of revenue. Return on Equity is reported at -587.6% and Return on Assets at -148.9%, metrics that reveal significant capital inefficiency and negative value generation per unit of equity and assets deployed, typical for pre-commercial ventures but concerning for capital preservation.
Avaliação de valorização
The valuation of Indaptus Therapeutics presents a complex picture with a trailing P/E ratio listed as N/A due to the lack of net income, while the forward P/E stands at -1.33, a figure that implies negative expected earnings trajectory or a forward estimate based on a denominator that is effectively negative. The price-to-book ratio is 1.28, suggesting that the market values the company at 28% above its book value, which often indicates that investors are pricing in significant future potential from the Decoy20 candidate despite current financial losses. The price-to-sales ratio is N/A, rendering this traditional valuation multiple inapplicable, while the EV/EBITDA multiple of 0.22 suggests an enterprise value that is extremely low relative to its negative earnings power. The stock trades within a volatile range defined by a 52-week high of $19.91 and a 52-week low of $1.51, meaning the current price sits at a level significantly below the recent peak but also well above the absolute floor of the trading year. The beta value of 0.99 indicates that the stock's price volatility moves in tandem with the broader market, lacking the typical high-beta characteristics often seen in small-cap biotechnology stocks during periods of clinical trial uncertainty.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both recorded as N/A, as the company has not yet generated commercial revenue to establish a growth rate. Consequently, there is no data to determine whether earnings are growing faster or slower than revenue, as the fundamental comparison requires positive revenue figures which are currently absent. As a non-dividend payer, the company offers a dividend yield of N/A and maintains a payout ratio of 0.0%, meaning all available cash resources are reinvested directly into research, development, and operational expansion rather than distributed to shareholders. The overall growth and income profile for Indaptus Therapeutics is characterized by a complete absence of current income generation and historical growth rates, relying entirely on the successful execution of its clinical development pipeline to eventually create shareholder value.